{
    "Overall_score": {
        "Correlation": 8,
        "Sentiment": 7,
        "Importance": 8,
        "Impact": 6,
        "Duration": 5,
        "Virality": 4,
        "Source_Score": 7,
        "Specificity": 9,
        "Sector_Spread": 3,
        "Tech_Mentions": 2
    },
    "Each_item": [
        {
            "News_content": "Japan's RegImmune joins with Pfizer on Type 1 diabetes antigen candidate",
            "Correlation": 7,
            "Sentiment": 6,
            "Importance": 7,
            "Impact": 5,
            "Duration": 4,
            "Virality": 3,
            "Source_Score": 7,
            "Specificity": 8,
            "Sector_Spread": 2,
            "Tech_Mentions": 1
        },
        {
            "News_content": "$PFE up 1.1% in PreM on release PALOMA-3 Trial for IBRANCE stopped early due to efficacy in patients w/ HR+ HER2: Metastatic Breast Cancer",
            "Correlation": 9,
            "Sentiment": 8,
            "Importance": 9,
            "Impact": 7,
            "Duration": 6,
            "Virality": 5,
            "Source_Score": 8,
            "Specificity": 10,
            "Sector_Spread": 4,
            "Tech_Mentions": 3
        },
        {
            "News_content": "Palbociclib continues to be a bright spot for Pfizer R&D. Breast cancer study stopped early on efficacy",
            "Correlation": 8,
            "Sentiment": 7,
            "Importance": 8,
            "Impact": 6,
            "Duration": 5,
            "Virality": 4,
            "Source_Score": 7,
            "Specificity": 9,
            "Sector_Spread": 3,
            "Tech_Mentions": 2
        }
    ]
}